Boehringer Ingelheim Second Transforming Science Day Boehringer Ingelheim Second Transforming Science Day World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day
License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments
Disentangling fibrosis Disentangling fibrosis Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Looking behind the scenes of Afrika Kommt! Looking behind the scenes of Afrika Kommt! Looking behind the scenes of Afrika Kommt! with Sabine and Eunice. I in D&I audio interview with reflections on a program designed to build bridges.
Boehringer acquires T3 Pharma Boehringer acquires T3 Pharma Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
The impact of carbon reduction projects The impact of carbon reduction projects Boehringer Ingelheim voluntarily contributes to carbon reduction projects that benefit sustainable development.
Experiences of living with cancer Experiences of living with cancer We know from speaking with people living with cancer and their loved ones, that it’s often the small moments that can be the most significant.
Advancing green chemistry for more sustainable medicines Advancing green chemistry for more sustainable medicines By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.
STOP Rabies: moving towards elimination STOP Rabies: moving towards elimination Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.
Social innovation: catalyst for sustainable health solutions Social innovation: catalyst for sustainable health solutions Supporting social innovators drives sustainable health solutions in underserved communities. Learn more about Boehringer Ingelheim Social Engagements.
Monoclonal antibodies Boehringer Ingelheim and Invetx Monoclonal antibodies Boehringer Ingelheim and Invetx Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
Plasmid DNA Production | BioXcellence Plasmid DNA Production | BioXcellence Discover our range of plasmid DNA production solutions from research to GMP.
Animal Health Partnering Contacts Animal Health Partnering Contacts Partnership and diversity of thought are powerful drivers of innovation. If you have a project you would like to discuss please reach out to us.
Lady, a guide dog in the office Lady, a guide dog in the office A great partnership between a Boehringer Ingelheim employee and her guide dog at work. Their relationship goes beyond the human-animal bond.
Algorithms to battle heartworm disease Algorithms to battle heartworm disease Partnership with the University of Melbourne uses AI to develop new veterinary solutions for pets
Closing healthcare gaps with continued vaccination campaigns Closing healthcare gaps with continued vaccination campaigns How we continue combating rabies through collaborative efforts and the use of drone delivery in rural Kenya.
Embracing diversity in clinical trials Embracing diversity in clinical trials At Boehringer Ingelheim, we understand the crucial need of embracing diversity in clinical trials as an opportunity to enable more equitable healthcare.
Collaboration Boehringer Ingelheim Veeva technology Collaboration Boehringer Ingelheim Veeva technology Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
Investment social engagements in Cowtribe veterinary startup Investment social engagements in Cowtribe veterinary startup Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance